Are we overtreating cancer patients? That's the provocative question at the heart of a fascinating debate about how we design clinical trials, and it could revolutionize how oncology treatments are developed and delivered. Dr. Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, a leading voice in medical oncology at Leiden University Medical Center, recently highlighted a groundbreaking paper by Bishal Gyawali that challenges the conventional wisdom surrounding de-escalation trials.
In a nutshell, the traditional approach to finding the optimal dose or duration of cancer therapies is flawed. We typically assume the highest tolerated dose is the best dose, and then try to prove that a lower dose is "almost as good." But here's where it gets controversial... proving something is "almost as good" requires massive, expensive trials to define a "non-inferiority margin" – a threshold of acceptable difference. And this is the part most people miss... even when these trials succeed, risk-averse clinicians often stick with the higher dose anyway, fearing any potential compromise in efficacy.
Gyawali's paper, championed by Dr. Barjesteh van Waalwijk van Doorn-Khosrovani, proposes a radical shift: instead of asking if a lower dose is almost as good, we should be asking: "Is the current standard therapy really better than a lower dose or shorter treatment?"
Think about it: the burden of proof should logically rest on justifying more treatment, not less. Why subject patients to potentially unnecessary side effects and costs if a less aggressive approach is equally effective? This is especially relevant considering the financial toxicity of cancer treatment, which can be a significant burden for patients and their families.
The beauty of this flipped perspective is that it requires smaller, faster, and cheaper studies to demonstrate that less can be more. As Dr. Barjesteh van Waalwijk van Doorn-Khosrovani points out, this approach is "so much more efficient." Gyawali's paper, titled "De-escalation trials do not always need to be non-inferiority - A case for superiority design de-escalation trials in oncology," delves into this concept in detail, using the SONIA trial as a key example. This trial likely investigated whether a less intensive chemotherapy regimen could achieve similar outcomes to a more aggressive one in a specific type of cancer.
Dr. Barjesteh van Waalwijk van Doorn-Khosrovani also directs attention to related work on dose-optimization by Gauthier Bouche, further emphasizing the importance of refining treatment strategies. And, she links to a compelling article titled "Less is more," reinforcing the idea that simpler, less intensive interventions can sometimes yield superior results.
The full article by Bishal Gyawali can be found in the JNCI: Journal of the National Cancer Institute. You can also explore more content featuring Dr. Sahar Barjesteh van Waalwijk van Doorn-Khosrovani on OncoDaily.
This paradigm shift in trial design has the potential to significantly impact patient care. But here's a key question: Are we, as a medical community, ready to embrace the idea that less can truly be more? Could this approach lead to better quality of life, reduced side effects, and lower healthcare costs, without compromising patient outcomes? Or do you believe the inherent risk aversion in medicine will always favor more aggressive treatments, even when evidence suggests otherwise? Share your thoughts in the comments below – are you convinced that de-escalation trials, designed with a superiority mindset, are the future of oncology?
